DEEJ(SZ:000423) Cai Jing Wang·2025-08-22 05:39Core Insights - The company's total revenue for the reporting period reached approximately 3.05 billion, representing a significant increase from the previous year's 2.75 billion, marking a growth of about 11% [1] Revenue Breakdown - By Industry: - Pharmaceutical industry generated approximately 2.99 billion, accounting for 97.88% of total revenue, up from 2.68 billion (97.66%) year-on-year [1] - Donkey breeding and trade contributed about 33.81 million, down from 37.26 million, representing a decline [1] - Other segments generated around 30.72 million, slightly up from 27.14 million [1] - By Product: - Revenue from Ejiao and related products increased by 11.50% to approximately 2.84 billion, while other pharmaceuticals and health products saw a growth of 7.06% to about 141.67 million [1] - Donkey breeding and trade revenue decreased by 9.27% to around 33.81 million [1] - By Region: - East China accounted for approximately 1.72 billion (56.32%), up from 1.40 billion (51.13%) [1] - South China generated about 301.12 million (9.87%), down from 358.63 million (13.05%) [1] - Other regions showed varied performance, with North China at 298.28 million (9.78%) and South West at 226.57 million (7.43%) [1]